´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.


NEWS
 Á¦¸ñ : [°øÁö] ½Å±Ô È«º¸ÀÚ·á Ãâ°£ – Áúº´¸ðµ¨ ¿¬±¸¸¦ À§ÇÑ Stem cell products
ÀÛ¼ºÀÏ : 2021.06.16
 ÀÛ¼ºÀÚ : ´ÙÄ«¶óÄÚ¸®¾Æ

 

TakaraÀÇ Áٱ⼼Æ÷ Àü¹® ºê·£µå, Cellartis

¼ö¸¹Àº Áٱ⼼Æ÷ °ü·Ã Á¦Ç°À» ÇÑ´«¿¡ »ìÆ캼 ¼ö ÀÖ´Â ½Å±Ô È«º¸ÀÚ·á°¡ Á¦À۵Ǿú½À´Ï´Ù.

 

Ȥ½Ã ¾Æ·¡¿Í °°Àº ¿¬±¸·Î Áٱ⼼Æ÷¸¦ ã°í °è½Å´Ù¸é?

- ½Å¾à °³¹ß (New drug discovery)

- ¸ÂÃã ÀÇÇÐ (Personalized medicine) ¿¬±¸

- Àç»ý ÀÇÇÐ (Regenerative medicine) ¿¬±¸

- µ¶¼º Æò°¡ ¸ðµ¨ (Toxicity testing model) °³¹ß ¹× È°¿ë

- ¼¼Æ÷ Ä¡·áÁ¦ °³¹ß (Cell therapy development)

- ºÐÈ­¹ý ¿¬±¸ (Differentiation protocol optimization)

 

À̹ÌÁö¸¦ Ŭ¸¯Çϼż­, ´Ù¾çÇÑ Á¦Ç°À» È®ÀÎÇϼ¼¿ä!

 

[ ¸ñÂ÷ ]

- hiPSC °ü·Ã Á¦Ç°

- hiPSC À¯·¡ Ectoderm À¯·¡ ¼¼Æ÷ ¹× °ü·Ã Á¦Ç°
a)
³ú/ÁßÃ߽Űæ°è ¸é¿ª¼¼Æ÷, Microglia

b) ÅÂ¾Æ ³ú Á¶Á÷ À¯·¡ÀÇ human Neural Stem Cell (hNSC)

- hiPSC À¯·¡ Endoderm À¯·¡ ¼¼Æ÷ ¹× °ü·Ã Á¦Ç°
   a)
³»¹è¿±, Endoderm ¼¼Æ÷¿Í ºÐÈ­ kit
   b)
°£¼¼Æ÷, Hepatocyte¿Í ºÐÈ­ kit, Àü¿ë ¹èÁö

   c) ÃéÀå beta cell

   d) ¼ÒÀå »óÇǼ¼Æ÷, intestinal epithelial cell

- hiPSC À¯·¡ Mesoderm À¯·¡ ¼¼Æ÷ ¹× °ü·Ã Á¦Ç°
   a)
Ç÷°ü ³»ÇǼ¼Æ÷, endothelial cell°ú ºÐÈ­ kit

   b) ÃÊ°í¼øµµ ½É±Ù¼¼Æ÷, Cardiomyocyte

 

 

¹®ÀÇ»çÇ×ÀÌ ÀÖÀ¸½Ã¸é ´ÙÄ«¶óÄÚ¸®¾Æ °í°´Áö¿ø¼¾ÅÍ·Î ¿¬¶ô ¹Ù¶ø´Ï´Ù.

           - TEL. 02-2081-2510

           - Mail. support@takara.co.kr

  

 

 ¸ñ·ÏÀ¸·Î